Equities research analysts predict that Astrazeneca PLC (NYSE:AZN) will announce earnings per share (EPS) of $0.46 for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Astrazeneca PLC’s earnings, with estimates ranging from $0.38 to $0.53. Astrazeneca PLC posted earnings of $1.21 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 62%. The firm is expected to report its next earnings report on Thursday, February 1st.

On average, analysts expect that Astrazeneca PLC will report full year earnings of $1.93 per share for the current year, with EPS estimates ranging from $1.82 to $2.28. For the next year, analysts anticipate that the company will report earnings of $1.84 per share, with EPS estimates ranging from $1.67 to $2.09. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Astrazeneca PLC.

Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.55. The company had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $6 billion. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.32 earnings per share.

A number of brokerages have recently commented on AZN. BidaskClub downgraded shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Liberum Capital downgraded shares of Astrazeneca PLC from a “buy” rating to a “hold” rating in a report on Thursday, September 14th. BNP Paribas upgraded shares of Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. Pareto Securities upgraded shares of Astrazeneca PLC from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Finally, Morgan Stanley downgraded shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. Astrazeneca PLC has a consensus rating of “Hold” and an average target price of $34.20.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate Astrazeneca PLC (AZN) to Post $0.46 Earnings Per Share” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/11/20/zacks-brokerages-anticipate-astrazeneca-plc-azn-to-post-0-46-earnings-per-share.html.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Belpointe Asset Management LLC acquired a new stake in Astrazeneca PLC in the third quarter valued at $309,000. Wealthcare Advisory Partners LLC acquired a new stake in Astrazeneca PLC in the third quarter valued at $184,000. Sterling Capital Management LLC acquired a new stake in Astrazeneca PLC in the third quarter valued at $248,000. Parallel Advisors LLC raised its holdings in Astrazeneca PLC by 36.3% in the third quarter. Parallel Advisors LLC now owns 9,522 shares of the company’s stock valued at $313,000 after acquiring an additional 2,537 shares in the last quarter. Finally, Westport Asset Management Inc. raised its holdings in Astrazeneca PLC by 100.0% in the third quarter. Westport Asset Management Inc. now owns 10,000 shares of the company’s stock valued at $341,000 after acquiring an additional 5,000 shares in the last quarter. 14.44% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Astrazeneca PLC (AZN) traded down $0.06 on Monday, reaching $33.46. 2,467,600 shares of the company’s stock were exchanged, compared to its average volume of 4,805,815. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $83,090.00, a PE ratio of 7.99, a P/E/G ratio of 3.16 and a beta of 0.79. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.60.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Get a free copy of the Zacks research report on Astrazeneca PLC (AZN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.